Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
18.36
+0.44 (2.46%)
At close: Feb 17, 2026, 4:00 PM EST
18.36
0.00 (0.00%)
After-hours: Feb 17, 2026, 5:28 PM EST
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $12.77M in the quarter ending September 30, 2025, with 38.54% growth. This brings the company's revenue in the last twelve months to $181.54M, up 1,112.27% year-over-year. In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M.
Revenue (ttm)
$181.54M
Revenue Growth
+1,112.27%
P/S Ratio
8.12
Revenue / Employee
$1,234,952
Employees
147
Market Cap
1.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.06B |
| AnaptysBio | 169.47M |
| Immatics | 99.45M |
| Intellia Therapeutics | 57.53M |
| Zenas BioPharma | 15.00M |
GLUE News
- 5 weeks ago - Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
- 5 weeks ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects - GlobeNewsWire
- 6 weeks ago - Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results - GlobeNewsWire
- 2 months ago - Why Is Monte Rosa Stock Trading Higher Today? - Benzinga
- 2 months ago - Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewsWire